Rilpivirine , ≥98% , 500287-72-9

CAS NO.：500287-72-9

Empirical Formula: C22H18N6

Molecular Weight: 366.42

MDL number: MFCD11046372

PRODUCT Properties

• Melting point: 245℃
• Boiling point: 634.1±65.0 °C(Predicted)
• Density: 1.27
• storage temp.: Refrigerator
• solubility: Acetone (Slightly), Chloroform (Slightly), DMSO (Slightly), Water (Very Slightly)
• pka: 4.56±0.10(Predicted)
• form: Solid
• color: Yellow
• InChI: InChI=1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3+
• InChIKey: YIBOMRUWOWDFLG-ONEGZZNKSA-N
• SMILES: C(#N)C1=CC=C(NC2=NC=CC(NC3=C(C)C=C(/C=C/C#N)C=C3C)=N2)C=C1

Description and Uses

In May 2011, the U.S. FDA approved rilpivirine in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) 1 infection in treatment-naive adult patients. Rilpivirine is a member of the nonnucleoside reverse transcriptase inhibitor (NNRTI) class of anti-HIV agents. It is highly potent against a range of wild-type HIV strains (EC50=0.07–1.0 nM),～10–20 timesmore potent than the NNRTI efavirenz (Sustiva), and active against HIV strains resistant to other NNRTIs. The discovery of rilpivirine was guided by molecular modeling and X-ray crystallography of HIV-1 RT complexed with inhibitors. The synthesis of rilpivirine is accomplished by an efficient 6-step route in which the key step is coupling of 4-((4-chloropyrimidin-2-yl)amino)benzonitrile with (E)-3-(4-amino-3,5-dimethylphenyl)acrylonitrile.

A novel non-nucleoside reverse transcriptase inhibitor. Rilpivirine seems to be well tolerated with less CNS disturbance than Efavirenz, and has non-teratogenic potential. An anti-HIV agent.

Safety

• Symbol(GHS): GHS07,GHS09
• Signal word: Warning
• Hazard statements: H319-H400-H302-H410
• Precautionary statements: P273-P391-P501-P264-P270-P301+P312-P330-P501-P273-P391-P501-P264-P280-P305+P351+P338-P337+P313P
• Hazardous Substances Data: 500287-72-9(Hazardous Substances Data)